However, our results demonstrated that treatment with bortezomib induced I-κBα degradation in DLBCL cell lines as well as in primary FL and DLBCL cells, in agreement with the finding by Hideshima and colleagues in multiple myeloma cells [16]. Here, NFKBIA is linked to diffuse large B-cell lymphoma.